The sale and usage of obesity medications in Finland have surged dramatically since the beginning of the 2020s. According to Kela, the Finnish social insurance institution, nearly 108,000 individuals purchased such medications in 2025, marking a 43% increase from the previous year. This uptick is starkly contrasted with just under 7,000 people who bought these medications in 2020, showcasing a growing recognition and response to obesity treatment in the country.

A pivotal factor behind this growth has been the increased uptake of semaglutide, a medication that has gained traction among patients who pay out-of-pocket for it. In 2025 alone, nearly 90,000 individuals in Finland used semaglutide for obesity treatment, with the most recognized preparation being Ozempic, manufactured by the Danish pharmaceutical company Novo Nordisk. Originally indicated for type 2 diabetes management, Ozempic's expansion into obesity care highlights a broader trend of repurposing medications to address the increasing rates of obesity in society.

While semaglutide leads the charge in obesity treatment, the introduction of newer weight-loss drugs is also gaining interest, although their adoption rates remain significantly lower at this time, especially in comparison to semaglutide. The current demographic utilizing these medications predominantly falls within the 45-65 age range, signaling a targeted approach in treating a health issue that has wide-ranging implications on public health, healthcare costs, and societal attitudes toward obesity management in Finland.